Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.39 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28033295 | 0.88 | LIPG (0.41) | LPLLIPGF11ESR2JAK2 | |
| SCHEMBL12533689 | 0.85 | LPL (0.40) | LPLLIPGF11ESR2JAK2 | |
| SCHEMBL441381 | 0.85 | LPL (0.44) | LPLLIPGF11ESR2JAK2 | |
| SCHEMBL7249357 | 0.85 | LIPG (0.42) | LPLLIPGF11ESR2UCHL1 | |
| SCHEMBL31081859 | 0.84 | LPL (0.37) | LPLLIPGF11ESR2JAK2 | |
| SCHEMBL14707184 | 0.84 | LIPG (0.39) | LPLLIPGF11ESR2JAK2 | |
| SCHEMBL17298116 | 0.83 | HTT (0.45) | LPLLIPGROCK1 | |
| SCHEMBL13198632 | 0.83 | LIPG (0.57) | LPLLIPGF11ESR2JAK2 | |
| SCHEMBL16865630 | 0.83 | LIPG (0.51) | LPLLIPGF11ESR2JAK2 | |
| SCHEMBL14696743 | 0.82 | LPL (0.40) | LPLLIPGF11ESR2CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053926-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-25 | — | — | US | disclosed |
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-10781184-B2 | Substituted benzazinones as antibacterial compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3181151-B1 | DETECTION OF HYDROGEN PEROXIDE | PROMEGA CORP (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-20180362474-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| EP-3386950-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-10-17 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| WO-2011049825-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | LPL 180/4885LIPG 272/4885F11 572/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | LPL 180/4885LIPG 272/4885F11 572/4885 |
| US-20210053926-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | LPXN, MLX, ZYX | LPL 30/4885LIPG 701/4885F11 2762/4885 |
| US-20180362474-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | LPXN, MLX, ZYX | LPL 30/4885LIPG 701/4885F11 2762/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | LPL 1082/4885LIPG 2028/4885F11 417/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | LPL 819/4885LIPG 1743/4885F11 340/4885 |
| US-10781184-B2 | Substituted benzazinones as antibacterial compounds | LPXN, MLX, ZYX | LPL 30/4885LIPG 701/4885F11 2762/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | LPL 819/4885LIPG 1743/4885F11 340/4885 |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR6, TLR1 | LPL 1070/4885LIPG 738/4885F11 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.